Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports first-quarter 2025 ...

Viking continued to build on the strong momentum achieved in 2024,” stated Brian Lian, Ph.D., chief executive officer of Viking. “Throughout the first quarter we continued to ramp up activities in ...

Dual Amylin and Calcitonin Receptor Agonist ... and Viking will retain ownership of all global rights to VK2735. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused ...

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight ...

Viking Therapeutics is poised for significant developments ... including the promising amylin agonist program. While challenges remain, particularly in manufacturing and competition, the company ...